[{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Beth Israel Deaconess Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Dietary Supplement","year":"2022","type":"Inapplicable","leadProduct":"Bovine Colostrum","moa":"\nLPS","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Beth Israel Deaconess Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Beth Israel Deaconess Medical Center \/ Beth Israel Deaconess Medical Center"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Neurology","graph2":"Phase IV","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ AbbVie Inc","highestDevelopmentStatusID":"11","companyTruncated":"Beth Israel Deaconess Medical Center \/ AbbVie Inc"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Fremanezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Phase IV","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beth Israel Deaconess Medical Center \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"11","companyTruncated":"Beth Israel Deaconess Medical Center \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Galcanezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Phase IV","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beth Israel Deaconess Medical Center \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"Beth Israel Deaconess Medical Center \/ Eli Lilly"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"DeGregorio Family Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Dendritic Cell Vaccine","moa":"Cellular tumor antigen p53 (TP53)","graph1":"Oncology","graph2":"Preclinical","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ DeGregorio Family Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Beth Israel Deaconess Medical Center \/ DeGregorio Family Foundation"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Veloxis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Veloxis Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Beth Israel Deaconess Medical Center \/ Veloxis Pharmaceuticals"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Botswana Harvard AIDS Institute Partnership | Gansu Provincial Maternal and Child Health Care Hospital | ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cabotegravir","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beth Israel Deaconess Medical Center \/ Botswana Harvard AIDS Institute Partnership | Gansu Provincial Maternal and Child Health Care Hospital | ViiV Healthcare","highestDevelopmentStatusID":"11","companyTruncated":"Beth Israel Deaconess Medical Center \/ Botswana Harvard AIDS Institute Partnership | Gansu Provincial Maternal and Child Health Care Hospital | ViiV Healthcare"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Neurology","graph2":"Phase I","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beth Israel Deaconess Medical Center \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Beth Israel Deaconess Medical Center \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Dupilumab","moa":"Interleukin-4 receptor subunit alpha","graph1":"Dermatology","graph2":"Phase II","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Beth Israel Deaconess Medical Center \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Boston University Charles River Campus | National Institute of Diabetes and Digestive and Kidney Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nicotinamide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2|Exotoxin A; Poly [ADP-ribose] polymerase 1| NAD-dependent protein deacylase sirtuin-5, mitochondrial| L-lactate dehydrogenase A chain","graph1":"Nephrology","graph2":"Phase I","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Boston University Charles River Campus | National Institute of Diabetes and Digestive and Kidney Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Beth Israel Deaconess Medical Center \/ Boston University Charles River Campus | National Institute of Diabetes and Digestive and Kidney Diseases"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Puma Biotechnology | Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Neratinib","moa":"Receptor protein-tyrosine kinase erbB-4 | Epidermal growth factor receptor erbB1 | Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Puma Biotechnology | Dana-Farber Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Beth Israel Deaconess Medical Center \/ Puma Biotechnology | Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Ortho Dermatologics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tretinoin","moa":"Retinoic acid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Ortho Dermatologics","highestDevelopmentStatusID":"11","companyTruncated":"Beth Israel Deaconess Medical Center \/ Ortho Dermatologics"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"AstraZeneca | Sirtex Medical | Dana-Farber Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Oncology","graph2":"Phase II","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beth Israel Deaconess Medical Center \/ AstraZeneca | Sirtex Medical | Dana-Farber Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Beth Israel Deaconess Medical Center \/ AstraZeneca | Sirtex Medical | Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Johnson & Johnson","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Johnson & Johnson","highestDevelopmentStatusID":"4","companyTruncated":"Beth Israel Deaconess Medical Center \/ Johnson & Johnson"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Quercis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Isoquercitrin","moa":"sP-selectin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Quercis Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Beth Israel Deaconess Medical Center \/ Quercis Pharma"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Genmab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Epcoritamab","moa":"T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase II","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Beth Israel Deaconess Medical Center \/ Genmab","highestDevelopmentStatusID":"8","companyTruncated":"Beth Israel Deaconess Medical Center \/ Genmab"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Boston Children's Hospital | Bristol Myers Squibb | Brigham and Women's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Abatacept","moa":"T-lymphocyte activation antigen CD86 | T-lymphocyte activation antigen CD80","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Boston Children's Hospital | Bristol Myers Squibb | Brigham and Women's Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Beth Israel Deaconess Medical Center \/ Boston Children's Hospital | Bristol Myers Squibb | Brigham and Women's Hospital"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Abrocitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beth Israel Deaconess Medical Center \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Beth Israel Deaconess Medical Center \/ Pfizer Inc"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deucravacitinib","moa":"Tyrosine-protein kinase TYK2","graph1":"Dermatology","graph2":"Phase II","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beth Israel Deaconess Medical Center \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Beth Israel Deaconess Medical Center \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Seed Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"DS-01","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Seed Health","highestDevelopmentStatusID":"8","companyTruncated":"Beth Israel Deaconess Medical Center \/ Seed Health"}]
Find Clinical Drug Pipeline Developments & Deals by Beth Israel Deaconess Medical Center
Details :
Niacinamide is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Kidney Diseases.
Details :
Abrocitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Post-Acute COVID-19 Syndrome.
Details :
The funding will be used for the development of a personalized dendritic cell/organoid-based vaccine for the treatment of patients with gastric cancer undergoing surgical resection.
Details :
Deucravacitinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hidradenitis Suppurativa.
Details :
Cabotegravir is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Details :
Gemcitabine is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Bile Duct Neoplasms.
Details :
Onabotulinumtoxin A is a Other Large Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Seizures.
Details :
Bovine Colostrum is a Dietary Supplement drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Celiac Disease.
Reset All
